New drugs in the therapy of multiple myeloma

Artur Jurczyszyn; Aleksander Skotnicki

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

4/2007
vol. 11

Send email

Copy url:

abstract:

New drugs in the therapy of multiple myeloma

Artur Jurczyszyn

,

Aleksander Skotnicki

Współczesna Onkologia (2007) vol. 11; 4 (186-194)

Online publish date: 2007/06/19

View full text Get citation

Multiple myeloma, a disorder of plasma cells, is the second most common haematological malignancy treated mainly in haematology or oncology clinics. Although treatable, multiple myeloma remains incurable in virtually all cases, with a median survival of 3-4 years. Fortunately for patients with this disease, traditional treatment paradigms have been challenged with the emergence of a number of new therapies entering clinical practice over the last 10 years. In this review, we focus on the use of thalidomide, lenalidomide and bortezomib in the treatment of myeloma. We present the current clinical experience with respect to efficacy and toxicity of these promising new agents and how the incorporation of these drugs with traditional therapies may improve the outcome for patients with multiple myeloma.

keywords:

New drugs in the therapy of multiple myeloma

Artur Jurczyszyn , Aleksander Skotnicki

multiple myeloma, treatment, thalidomide, lenalidomide, bortezomib

Artur Jurczyszyn

,

Aleksander Skotnicki